Matthew Biegler
Stock Analyst at Oppenheimer
(3.59)
# 849
Out of 5,090 analysts
86
Total ratings
38.16%
Success rate
10.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $32.63 | +37.91% | 1 | Dec 4, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $22 → $45 | $26.65 | +68.86% | 8 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $11.30 | +32.74% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $13.75 | +60.00% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $18.01 | +55.47% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $2.39 | +234.73% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $3.96 | +76.99% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.44 | +527.18% | 2 | May 14, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $8.15 | +1,863.19% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $12.82 | +251.01% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $121.36 | -5.24% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $35.59 | +48.92% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $22.31 | +47.92% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.40 | +1,328.57% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.69 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $6.93 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.31 | +50.38% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.10 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.07 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.02 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.82 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.95 | - | 2 | Dec 22, 2022 |
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $32.63
Upside: +37.91%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $22 → $45
Current: $26.65
Upside: +68.86%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $11.30
Upside: +32.74%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $13.75
Upside: +60.00%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $18.01
Upside: +55.47%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $2.39
Upside: +234.73%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $3.96
Upside: +76.99%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.44
Upside: +527.18%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $8.15
Upside: +1,863.19%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $12.82
Upside: +251.01%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $121.36
Upside: -5.24%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $35.59
Upside: +48.92%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $22.31
Upside: +47.92%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.40
Upside: +1,328.57%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.69
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $6.93
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $9.31
Upside: +50.38%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.10
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.07
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.02
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.82
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.95
Upside: -